source
- FDA grants accelerated approval for Rybrevant Faspro in recurrent/metastatic head and neck cancerThe U.S. Food and Drug Administration granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for adults with recurrent or metastatic head and neck squamous cell carci…
- RevMed stock rises on early Rasonque sales as whistleblower sues Madrigal over MASH safetyRevMed announced its first sales figures for Rasonque, a therapy targeting pancreatic cancer, and the news sent the company's shares higher. The company said the early sales data reflect market up…